Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS, Oon ML, Wang S, Tan SY, Ng SB.
Pathology. 2020 Jan;52(1):111-127. doi: 10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22.
Natural killer-cell neoplasms.
Greer JP, Mosse CA.
Curr Hematol Malig Rep. 2009 Oct;4(4):245-52. doi: 10.1007/s11899-009-0032-3.
NK cells and ILCs in tumor immunotherapy.
Sivori S, Pende D, Quatrini L, Pietra G, Della Chiesa M, Vacca P, Tumino N, Moretta F, Mingari MC, Locatelli F, Moretta L.
Mol Aspects Med. 2021 Aug;80:100870. doi: 10.1016/j.mam.2020.100870. Epub 2020 Aug 13.
A modern view of LGL leukemia.
Marchand T, Lamy T, Loughran TP Jr.
Blood. 2024 Oct 31;144(18):1910-1923. doi: 10.1182/blood.2023021790.
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Sanchez-Correa B, Campos C, Pera A, Bergua JM, Arcos MJ, Bañas H, Casado JG, Morgado S, Duran E, Solana R, Tarazona R.
Cancer Immunol Immunother. 2016 Apr;65(4):453-63. doi: 10.1007/s00262-015-1720-6. Epub 2015 Jun 10.
Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J, Niu T.
J Hematol Oncol. 2020 Dec 7;13(1):167. doi: 10.1186/s13045-020-00996-x.
Natural killer cell neoplasms.
Liang X, Graham DK.
Cancer. 2008 Apr 1;112(7):1425-36. doi: 10.1002/cncr.23316.
Natural killer cell-triggering receptors in patients with acute leukaemia.
Fauriat C, Marcenaro E, Sivori S, Rey J, Gastaut JA, Moretta A, Olive D, Costello RT.
Leuk Lymphoma. 2003 Oct;44(10):1683-9. doi: 10.1080/1042819031000104006.
Natural killer cells.
Kay NE.
Crit Rev Clin Lab Sci. 1986;22(4):343-59. doi: 10.3109/10408368509165790.
Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias.
Khan M, Mansoor AE, Olson AL.
Future Oncol. 2016 Oct;12(19):2179-82. doi: 10.2217/fon-2016-0125. Epub 2016 Jun 2.
